X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (58) 58
male (46) 46
female (43) 43
index medicus (43) 43
middle aged (42) 42
oncology (40) 40
aged (35) 35
adult (30) 30
lung neoplasms - drug therapy (28) 28
chemotherapy (25) 25
carcinoma, non-small-cell lung - drug therapy (23) 23
cancer (22) 22
lung neoplasms - pathology (20) 20
treatment outcome (18) 18
care and treatment (17) 17
lung neoplasms - mortality (17) 17
aged, 80 and over (15) 15
carcinoma, non-small-cell lung - pathology (15) 15
disease-free survival (15) 15
lung cancer, non-small cell (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
respiratory system (14) 14
carcinoma, non-small-cell lung - mortality (13) 13
hematology, oncology and palliative medicine (13) 13
lung cancer (13) 13
antineoplastic agents - therapeutic use (12) 12
mutation (12) 12
neoplasm staging (11) 11
survival (11) 11
trial (10) 10
pulmonary/respiratory (9) 9
survival analysis (9) 9
antineoplastic agents (8) 8
antineoplastic agents - adverse effects (8) 8
carboplatin (8) 8
cisplatin - administration & dosage (8) 8
clinical trials (8) 8
life sciences (8) 8
lung neoplasms - genetics (8) 8
metastasis (8) 8
non-small cell lung cancer (8) 8
receptor, epidermal growth factor - genetics (8) 8
antimitotic agents (7) 7
carcinoma, non-small-cell lung - genetics (7) 7
gefitinib (7) 7
medicine, general & internal (7) 7
prospective studies (7) 7
protein kinase inhibitors - therapeutic use (7) 7
analysis (6) 6
antineoplastic agents - administration & dosage (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
carboplatin - administration & dosage (6) 6
carcinoma, non-small-cell lung - therapy (6) 6
cisplatin (6) 6
combination (6) 6
docetaxel (6) 6
erlotinib (6) 6
kaplan-meier estimate (6) 6
open-label (6) 6
proportional hazards models (6) 6
quinazolines - therapeutic use (6) 6
radiotherapy (6) 6
research (6) 6
risk factors (6) 6
therapy (6) 6
cell lung-cancer (5) 5
cetuximab (5) 5
cystic fibrosis - genetics (5) 5
lung neoplasms - therapy (5) 5
medicine & public health (5) 5
neoplasms (5) 5
nsclc (5) 5
patients (5) 5
product development (5) 5
tumors (5) 5
vas deferens - abnormalities (5) 5
1st-line treatment (4) 4
abridged index medicus (4) 4
administration, oral (4) 4
bevacizumab (4) 4
clinical-trials (4) 4
deoxycytidine - administration & dosage (4) 4
deoxycytidine - analogs & derivatives (4) 4
disease progression (4) 4
erlotinib hydrochloride - therapeutic use (4) 4
exons (4) 4
hypersensitivity (4) 4
immunotherapy (4) 4
lung neoplasms (4) 4
multicenter (4) 4
neoplasm metastasis (4) 4
oncology, experimental (4) 4
paclitaxel (4) 4
paclitaxel - administration & dosage (4) 4
pemetrexed (4) 4
predictive value of tests (4) 4
quality of life (4) 4
resistance (4) 4
retrospective studies (4) 4
surgery (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 726 - 736
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9652, pp. 1809 - 1818
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MVA-MUC1-IL2 | PROSTATE-CANCER | VACCINE | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 744 - 752
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2004, Volume 22, Issue 9, pp. 1589 - 1597
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 7/2013, Volume 40, Issue 7, pp. 985 - 996
Journal Article
Journal Article